Some applications of the present invention relate in general to valve replacement. More specifically, some applications of the present invention relate to prosthetic valves for replacement of a cardiac valve.
Ischemic heart disease causes regurgitation of a heart valve by the combination of ischemic dysfunction of the papillary muscles, and the dilatation of the ventricle that is present in ischemic heart disease, with the subsequent displacement of the papillary muscles and the dilatation of the valve annulus.
Dilation of the annulus of the valve prevents the valve leaflets from fully coapting when the valve is closed. Regurgitation of blood from the ventricle into the atrium results in increased total stroke volume and decreased cardiac output, and ultimate weakening of the ventricle secondary to a volume overload and a pressure overload of the atrium.
A percutaneously-deliverable (e.g., transluminally-deliverable) mechanical prosthetic valve, comprising a tubular element and a valve member is described. Typically, the tubular element and valve member are restrained in respective compressed configurations for delivery, and automatically expand into respective expanded configurations when released at the native valve.
There is therefore provided, in accordance with an application of the present invention, apparatus for regulating blood flow of a subject, the apparatus including a prosthetic valve, the prosthetic valve:
including:
having:
In an application, the prosthetic valve is configured to function as a check valve when in the expanded configuration thereof, and not when in the compressed configuration thereof.
In an application, in the compressed configuration, the valve member is coupled to the tubular element.
In an application, in the compressed configuration, the valve member is disposed within the lumen.
In an application:
the lumen has a first end and a second end, and
the valve member, when the valve is in the expanded configuration thereof:
In an application, in the expanded configuration, the valve member is configured to move between the open and closed states in response to changes in relative pressure between the first and second ends of the lumen.
In an application, in the expanded configuration, the valve member, in at least the closed state thereof, has a diameter that is no more than 20 percent smaller than the expanded width of the lumen.
In an application, the valve member has a compressed diameter in the compressed configuration of the prosthetic valve, and an expanded diameter in the in the expanded configuration of the prosthetic valve, and the expanded diameter is at least twice as great as the compressed diameter.
In an application, in the expanded configuration, the prosthetic valve is configured to act as a check valve.
In an application, in the expanded configuration, the valve member is configured to move toward the open state when pressure at the first end of the lumen is greater than pressure at the second end of the lumen, and to move toward the closed state when pressure at the second end of the lumen is greater than pressure at the first end of the lumen.
In an application, the valve member is coupled to the tubular element at at least two coupling points, the coupling points defining an axis therebetween.
In an application, the valve member is configured to move between the open and closed states thereof, by rotating around the axis between the coupling points.
In an application, the valve member is configured to move between the open and closed states thereof, by deflecting around the axis between the coupling points.
In an application, the apparatus further includes a coupling rod, coupled to the coupling points, and coupled to the valve member along the axis between the coupling points, and the valve member is configured to move between the open and closed states thereof, by bending around the coupling rod.
In an application, the prosthetic valve includes a coupling element that includes at least one strut, the strut being coupled to the tubular element, and to the valve member at a coupling point that is generally midway across a diameter of the valve member, and the valve member is configured to move between the open and closed states by deflecting from the coupling point.
In an application, the valve member is configured to move between the open and closed states by collapsing and expanding.
In an application, the valve member is configured to move between the open and closed states thereof without changing a shape thereof.
In an application, the prosthetic valve is configured such that, when the valve member moves toward the open state, at least part of the valve member moves toward the first end of the lumen and at least part of the valve member moves toward the second end of the lumen.
In an application, the valve member is configured to move between the open and closed states thereof by changing a shape thereof.
In an application, the valve member is configured to be biased toward being in the closed state thereof.
In an application, in the compressed configuration, the prosthetic valve has a greatest transverse diameter of less than 12 mm.
In an application, in the compressed configuration, the prosthetic valve has a greatest transverse diameter of less than 9 mm.
In an application, in the compressed configuration, the prosthetic valve has a greatest transverse diameter of less than 6 mm.
In an application, the prosthetic valve is intracorporeally expandable from the compressed configuration to the expanded configuration.
In an application, the prosthetic valve is configured to be percutaneously delivered in the constrained configuration thereof, by being restrained in the compressed configuration during the percutaneous delivery, and the prosthetic valve is configured to automatically expand toward the expanded configuration thereof when no longer restrained.
The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:
Reference is made to
Typically, length d1 is greater than 10 mm and/or less than 30 mm (e.g., 10-30 mm). Typically, width d2 is greater than 20 mm and/or less than 40 mm (e.g., 20-40 mm, such as 30 mm). That is, in the expanded configuration thereof (as shown in
Typically, tubular member 22 comprises a frame 26 that defines a circumferentially-repeating arrangement of cells 27. Typically, frame 26 defines, along length d1, longitudinal columns c1 comprising one cell 27, alternating with longitudinal columns c2 comprising two cells. Typically, frame 26 defines circumferential rows comprising more than 10 and/or less than 25 cells 27 (e.g., 18 cells). It is to be noted, however, that the scope of the invention includes other configurations of frame 26.
Typically, valve member 24 has a width d4 that is no more than 20 percent smaller than width d2 of tubular element 22 (e.g., no more than 10 percent smaller, such as no more than 5 percent smaller). For applications in which tubular element 22 is generally cylindrical and valve member is generally disc-shaped, widths d3 and d4 represent transverse cross-sectional diameters of lumen 23 and valve member 24, respectively, and the diameter of valve member 24 is typically no less than 20 percent smaller than the diameter of lumen 23 (i.e., no less than 20 percent smaller than the inner diameter of tubular element 22). Thereby, width d4 is typically greater than 20 mm and/or less than 40 mm (e.g., 20-40 mm, such as 30 mm).
Typically, valve member 24 comprises a frame 28 that defines an outer edge 30, an inner edge 32, and a radially-repeating arrangement of cells 29, disposed between the inner and outer edges. Inner edge 32 defines an opening 42, the presence of which facilitates compression of valve member 24 into the compressed configuration thereof (e.g., as described with reference to
For clarity,
Valve 20 is configured to be percutaneously (e.g., transcatheterally and/or transluminally, such as transfemorally) delivered to the native heart valve of a subject, by being compressed (e.g., “crimped”) into the compressed configuration thereof (i.e., a delivery configuration thereof). Valve 20 is typically configured to be restrained in the compressed configuration (e.g., by an overtube) during delivery of the valve, and to automatically move into an expanded configuration when released (e.g., by being deployed from the overtube). Typically, frames 26 and 28 comprise a shape-memory material such as, but not limited to, nitinol, which facilitates this automatic expansion.
Covering 40 typically covers inner surface 36 of cylindrical element 22 and at least one side of valve member 24, including opening 42. Opening 42 is thereby an opening in frame 28 but typically not an opening in covering 40, and thereby typically not an opening through the entire of valve member 24 (
As described hereinabove, tubular element 22 is typically generally cylindrical.
That is, element 22 is typically generally cylindrical in the expanded configuration thereof. Tubular element 22 is typically also generally cylindrical in the compressed configuration thereof. In the compressed configuration thereof, tubular element 22 (e.g., lumen 23 thereof) has a width d6 (e.g., a diameter) that is smaller than width d2 of the tubular element in the compressed configuration thereof. Typically, width d2 is more than 1.5 times (e.g., more than 4 times) greater than width d6.
As described hereinabove, valve member 24 is typically generally disc-shaped. That is, member 24 is typically generally disc-shaped in the expanded configuration thereof. In the compressed configuration thereof, valve member 24 is typically elongate, such as generally cylindrical, and has a width (e.g., a diameter) d7. Typically, width d4 (
Valve member 24 is typically disposed in lumen 23 of tubular element 22, in both the compressed configuration and the expanded configuration of valve 20. Valve member 24 is coupled to tubular element 22 at one or more (e.g., two) coupling points 60. Coupling points 60 comprise a coupling element 61, which may comprise a hinge, a connector (e.g., a connecting wire or suture), or any other suitable coupling element. For some applications, and as shown in
Typically, width d6 is greater than 2 mm and/or less than 12 mm (e.g., 2-10 mm, such as 3-6 mm). Typically, width d7 is greater than 2 mm and/or less than 10 mm (e.g., 2-8 mm, such as 2-6 mm). Typically, valve member 24 is configured to be compressible such that width d7 is smaller than width d6 in a maximally-compressed configuration of cylindrical element 22, e.g., such that cylindrical element 22 is compressible to generally the same width in the presence or absence of valve member 24.
As described hereinabove, prosthetic valve 20 is configured to be placed (i.e., implanted) at a native heart valve of a subject, and to replace native functionality of the native valve. Prosthetic valve 20 is configured to act as a one-way valve (e.g., a check valve). That is, prosthetic valve 20 is configured to generally allow blood to flow in a first direction through lumen 23 of tubular element 22, and to inhibit blood from flowing in a second direction through the lumen. Typically, prosthetic valve 20 resembles and/or is configured to act as a “tilting disc” valve, as is known in the valve art. Valve member 24, disposed in lumen 23 of tubular element 22, provides valve functionality by being configured to move between an open state and a closed state in response to changes in relative pressure between each end of the lumen of tubular element 22 (i.e., in response to changes in relative pressure between blood at each end of the lumen; e.g., as described hereinbelow with reference to
Reference is made to
For some applications, valve member 24 has a shape that is different to a flat disc.
It is to be noted that
Reference is made to
Valve member 24 is coupled to tubular element 22 at one or more coupling points 60, such that the valve member can rotate between (1) an open state in which the valve member generally allows fluid (e.g., blood) to flow through lumen 23, and (2) a closed state in which the valve member generally blocks lumen 23, thereby generally inhibiting fluid from flowing through the lumen. Typically, valve member 24 is coupled to tubular element 22 at two coupling points 60 (e.g., coupling points 60a and 60b), such that the valve member can rotate around an axis a1 between the two coupling points. Typically, valve member 24 does not change shape when moving between the open and closed states.
Typically, coupling points 60a and 60b do not lie on a central transverse axis a2 of tubular element 22. That is, axis a1 is typically a non-diameter chord of a transverse cross-section of tubular element 22. Such a configuration typically facilitates the functioning of valve 20 as a tilting-disc valve, as is known in the art.
Valve 20 is configured such that valve member 24 moves between the open state and the closed state in response to changes in relative fluid pressure between each end of lumen 23, and thereby valve 20 is configured to act as a one-way valve (e.g., a check valve). In the open state, a first end 64 of tubular element 22 is in fluid communication with a second end 66 of the tubular element. In the closed state, fluid communication between the two ends is reduced, compared to in the open state (e.g., the first and second ends are substantially not in fluid communication).
As shown in
Valve member 24 is typically configured (e.g., dimensioned) such that, in the closed state, outer edge 30 (see
For some applications of the invention, valve 20 further comprises at least one valve seat 62, configured to facilitate contact (e.g., sealing) between valve member 24 and tubular element 22. For some such applications, and as shown in
Seats 62a and 62b protrude into lumen 23 of tubular element 22, so as to facilitate sealing between the tubular element and valve member 24. For some applications, the seats comprise a sealing element, such as a sealing surface, to further facilitate such sealing. Typically, the seats and/or sealing elements comprise a fabric, a resin and/or a polymer and are configured to fold, crumple, contract, and/or compress when valve 20 is compressed into the compressed configuration thereof, and to unfold, uncrumple, expand, and/or uncompress into the configuration shown in
Reference is made to
Typically, tubular element 82 comprises and/or has features of tubular element 22, described hereinabove (e.g., with reference to
Typically, valve member 84 comprises and/or has features of valve member 24, described hereinabove (e.g., with reference to
Typically, the dimensions of valve 80 (e.g., the dimensions of tubular element 82 and valve member 84) are similar (e.g., the same as) those of valve 20 (e.g., of tubular element 22 and valve member 24), described hereinabove, mutatis mutandis.
As shown in
Valve 80 comprises covering 40, which covers at least part of the frames of tubular element 82 and valve member 84 (e.g., as described hereinabove for valve 20, mutatis mutandis). Typically, covering 40 covers an inner surface 96 of tubular element 82, and at least one side of valve member 84. Valve 80 is configured to be delivered percutaneously (e.g., transcatheterally and/or transluminally, such as transfemorally), e.g., as described hereinabove with respect to valve 20, mutatis mutandis.
Valve member 84 is coupled to tubular element 82 at one or more (e.g., two) coupling points 100, in both the compressed and expanded configurations of valve 80. Coupling points 100 comprise a coupling element, which may comprise a hinge, a connector (e.g., a connecting wire or suture), or any other suitable coupling element. For some applications, and as described for coupling element 61 hereinabove, each coupling element of valve 80 comprises a protrusion of the frame of the valve member protruding into a slot defined by frame of the tubular element.
Valve member 84 is coupled to tubular element 82 at the one or more coupling points 100, such that the valve member can move between (1) an open state in which the valve member generally allows fluid (e.g., blood) to flow through lumen 83, and (2) a closed state in which the valve member generally blocks lumen 83, thereby generally inhibiting fluid from flowing though the lumen.
Typically, valve member 84 is coupled to tubular element 82 at two coupling points 100 (e.g., coupling points 100a and 100b), such that valve member 84 can deflect (e.g., bend) around an axis a3 between the two coupling points. Typically, coupling points 100a and 100b lie on a central transverse axis a4 (e.g., a diameter) of tubular element 82, and axis a3 acts as a central fixed axis around which each resulting half of valve member 84 deflects. Further typically, and as shown in
For some applications of the invention, valve member 84 comprises valve member 24, described hereinabove. For some applications of the invention, valve member 84 is unevenly rigid. For example, the valve member may define an area of increased flexibility at and/or around axis a3 (e.g., at and/or around coupling rod 92), so as to facilitate the movement of valve member 84 between the open and closed states described hereinabove. It is to be noted that, whereas valve member 24 of prosthetic valve 20 typically moves between the open and closed states thereof without changing shape, valve member 84 of prosthetic valve 80 typically does change shape when moving between the open and closed states thereof.
Valve 80 is configured such that valve member 84 moves between the open state and the closed state in response to changes in relative fluid pressure between each end of lumen 83, and thereby valve 80 is configured to act as a one-way valve (e.g., a check valve). In the open state, a first end 104 of tubular element 82 is in fluid communication with a second end 106 of the tubular element. In the closed state, fluid communication between the two ends is reduced, compared to in the open state (e.g., the first and second ends are substantially not in fluid communication).
As shown in
For some applications of the invention, movement of valve member 84 between the open and closed states thereof is driven primarily by the relative pressure at each end of lumen 83. For some applications, valve member 84 is biased (e.g., shape-set) toward assuming the closed state, e.g., in the absence of any substantial forces thereon.
Valve member 84 is typically configured (e.g., dimensioned) such that, in the closed state, an outer edge 90 of the valve member is disposed close to inner surface 96 of tubular element 82 (e.g., the valve member is in close contact with the inner surface of the tubular element). For example, the diameter of valve member 84 is typically no more than 20 percent smaller than the width of the lumen of the tubular element.
For some applications of the invention, valve 80 further comprises a valve seat 102, configured to facilitate contact (e.g., sealing) between valve member 84 and tubular element 82. For some such applications, and as shown in
Typically, the seat and/or sealing element comprises a fabric, a resin and/or a polymer and is configured to fold, crumple, contract, and/or compress when valve 80 is compressed into the compressed configuration thereof (
Reference is made to
Typically, tubular element 122 comprises and/or has features of tubular element 22 and/or tubular element 82, described hereinabove (e.g., with reference to
Typically, valve member 124 comprises and/or has features of valve member 24 and/or valve member 84, described hereinabove (e.g., with reference to
Typically, the dimensions of valve 120 (e.g., the dimensions of tubular element 122 and valve member 124) are similar (e.g., the same as) those of valve 20 (e.g., of tubular element 22 and valve member 24), described hereinabove, mutatis mutandis.
As shown in
Valve 120 comprises covering 40, which covers at least part of the frames of tubular element 122 and valve member 124 (e.g., as described hereinabove for valves 20 and 80, mutatis mutandis). Typically, covering 40 covers an inner surface 136 of tubular element 82, and at least one side of valve member 84. Valve 80 is configured to be delivered percutaneously (e.g., transcatheterally and/or transluminally, such as transfemorally), e.g., as described hereinabove with respect to valves 20 and 80, mutatis mutandis.
Valve member 124 is coupled to tubular element 122 at at least one coupling point 140, in both the compressed and expanded configurations of valve 120. Valve 120 comprises a coupling element 141, which may comprise a hinge, a connector (e.g., a connecting wire or suture), or any other suitable coupling element. Typically, and as shown in
Valve member 124 is coupled to tubular element 122 such that the valve member can move between (1) an open state in which the valve member generally allows fluid (e.g., blood) to flow through lumen 123, and (2) a closed state in which the valve member generally blocks lumen 123, thereby generally inhibiting fluid from flowing though the lumen.
For some applications of the invention, valve member 124 comprises valve member 24 and/or valve member 84, described hereinabove. For some applications of the invention, valve member 124 is unevenly rigid. For example, the valve member may define one or more areas of increased flexibility that extend radially from coupling point 140 so as to facilitate the movement of valve member 124 between the open and closed states described hereinabove.
Valve 120 is configured such that valve member 124 moves between the open state and the closed state in response to changes in relative fluid pressure between each end of lumen 123, and thereby valve 120 is configured to act as a one-way valve (e.g., a check valve). In the open state, a first end 144 of tubular element 122 is in fluid communication with a second end 146 of the tubular element. In the closed state, fluid communication between the two ends is reduced, compared to in the open state (e.g., the first and second ends are substantially not in fluid communication).
As shown in
For some applications of the invention, movement of valve member 124 between the open and closed states thereof is driven primarily by the relative pressure at each end of lumen 123. For some applications, valve member 124 is biased (e.g., shape-set) toward assuming the closed state, e.g., in the absence of any substantial forces thereon.
Valve member 124 is typically configured (e.g., dimensioned) such that, in the closed state, an outer edge 130 of the valve member is disposed close to inner surface 136 of tubular element 122 (e.g., the valve member is in close contact with the inner surface of the tubular element). For example, the diameter of valve member 124 is typically no more than 20 percent smaller than the width of the lumen of the tubular element.
For some applications of the invention, valve 120 further comprises a valve seat 142, configured to facilitate contact (e.g., sealing) between valve member 124 and tubular element 122. For some such applications, and as shown in
Typically, the seat and/or sealing element comprises a fabric, a resin and/or a polymer and is configured to fold, crumple, contract, and/or compress when valve 120 is compressed into the compressed configuration thereof (
Reference is again made to
Reference is again made to
Reference is again made to
Typically, the prosthetic valves described herein arc implanted (and/or configured to be implanted) at a native valve of the subject such that the first end is upstream of the second end. For example, the valves may be implanted at an atrioventricular valve of the subject (e.g., a mitral valve of the subject) such that the first end is disposed in an atrium of the subject (e.g., a left atrium of the subject) and the second end is disposed in a ventricle of the subject (e.g., a left ventricle of the subject). Thereby, the prosthetic valve replaces one-way valve functionality of the native valve, with one-way valve functionality of the prosthetic valve.
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present application is a Continuation of U.S. Ser. No. 15/354,504 to HaCohen et al., entitled “Percutaneously-deliverable mechanical valve,” which published as US 2017/0065407 (now U.S. Pat. No. 10,045,845), which is a Continuation of U.S. Ser. No. 14/442,541 to HaCohen et al., entitled “Percutaneously-deliverable mechanical valve,” which published as US 2016/0213473 (now U.S. Pat. No. 9,498,332); which is the US National Phase of PCT IL2013/050937 to HaCohen et al, entitled “Percutaneously-deliverable mechanical valve,” which published as WO 2014/076696; which is a Continuation of U.S. patent application Ser. No. 13/675,119 to HaCohen et al., entitled “Percutaneously-deliverable mechanical valve,” filed on Nov. 13, 2012 (now U.S. Pat. No. 8,628,571), which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4275469 | Gabbay | Jun 1981 | A |
4423525 | Vallana et al. | Jan 1984 | A |
4853986 | Allen | Aug 1989 | A |
4994077 | Dobben | Feb 1991 | A |
5078739 | Martin | Jan 1992 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5405378 | Strecker | Apr 1995 | A |
5443500 | Sigwart | Aug 1995 | A |
5647857 | Anderson et al. | Jul 1997 | A |
5765682 | Bley et al. | Jun 1998 | A |
5873906 | Lau et al. | Feb 1999 | A |
5980565 | Jayaraman | Nov 1999 | A |
6010530 | Goicoechea | Jan 2000 | A |
6019787 | Richard et al. | Feb 2000 | A |
6059827 | Fenton, Jr. | May 2000 | A |
6165210 | Lau et al. | Dec 2000 | A |
6193745 | Fogarty et al. | Feb 2001 | B1 |
6287339 | Vazquez et al. | Sep 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6334873 | Lane et al. | Jan 2002 | B1 |
6350278 | Lenker et al. | Feb 2002 | B1 |
6352561 | Leopold et al. | Mar 2002 | B1 |
6402780 | Williamson, IV et al. | Jun 2002 | B2 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6551350 | Thornton et al. | Apr 2003 | B1 |
6558396 | Inoue | May 2003 | B1 |
6719788 | Cox | Apr 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7175656 | Khairkhahan | Feb 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7351256 | Hojeibane et al. | Apr 2008 | B2 |
7374573 | Gabbay | May 2008 | B2 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7445630 | Lashinski et al. | Nov 2008 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7625403 | Krivoruchko | Dec 2009 | B2 |
7682380 | Thornton et al. | Mar 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7758632 | Hojeibane et al. | Jul 2010 | B2 |
7780726 | Seguin | Aug 2010 | B2 |
7785341 | Forster et al. | Aug 2010 | B2 |
7837727 | Goetz et al. | Nov 2010 | B2 |
7942927 | Kaye et al. | May 2011 | B2 |
7955377 | Melsheimer | Jun 2011 | B2 |
8016882 | Macoviak et al. | Sep 2011 | B2 |
8048138 | Sullivan et al. | Nov 2011 | B2 |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8070708 | Rottenberg et al. | Dec 2011 | B2 |
8070800 | Lock et al. | Dec 2011 | B2 |
8118866 | Herrmann et al. | Feb 2012 | B2 |
8142496 | Berreklouw | Mar 2012 | B2 |
8167935 | McGuckin, Jr. et al. | May 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8267988 | Hamer et al. | Sep 2012 | B2 |
8337541 | Quadri et al. | Dec 2012 | B2 |
8343213 | Salahieh et al. | Jan 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8408214 | Spenser | Apr 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8454686 | Alkhatib | Jun 2013 | B2 |
8545544 | Spenser et al. | Oct 2013 | B2 |
8551161 | Dolan | Oct 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8628569 | Benichou et al. | Jan 2014 | B2 |
8628571 | Hacohen et al. | Jan 2014 | B1 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8657872 | Seguin | Feb 2014 | B2 |
8679174 | Ottma et al. | Mar 2014 | B2 |
8685086 | Navia et al. | Apr 2014 | B2 |
8728155 | Montorfano et al. | May 2014 | B2 |
8784472 | Eidenschink | Jul 2014 | B2 |
8784481 | Alkhatib et al. | Jul 2014 | B2 |
8795355 | Alkhatib | Aug 2014 | B2 |
8795356 | Quadri et al. | Aug 2014 | B2 |
8795357 | Yohanan et al. | Aug 2014 | B2 |
8808366 | Braido et al. | Aug 2014 | B2 |
8852261 | White | Oct 2014 | B2 |
8852272 | Gross et al. | Oct 2014 | B2 |
8870948 | Erzherger et al. | Oct 2014 | B1 |
8870949 | Rowe | Oct 2014 | B2 |
8894702 | Quadri et al. | Nov 2014 | B2 |
8932343 | Alkhatib et al. | Jan 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8979922 | Jayasinghe et al. | Mar 2015 | B2 |
8998982 | Richter et al. | Apr 2015 | B2 |
9005273 | Salahieh et al. | Apr 2015 | B2 |
9023100 | Quadri et al. | May 2015 | B2 |
9034032 | McLean et al. | May 2015 | B2 |
9034033 | McLean et al. | May 2015 | B2 |
9039757 | McLean et al. | May 2015 | B2 |
9050188 | Schweich, Jr. et al. | Jun 2015 | B2 |
9072603 | Tuval et al. | Jul 2015 | B2 |
9125740 | Morriss et al. | Sep 2015 | B2 |
9155619 | Liu et al. | Oct 2015 | B2 |
9226839 | Kariniemi et al. | Jan 2016 | B1 |
9232995 | Kovalsky et al. | Jan 2016 | B2 |
9241790 | Lane et al. | Jan 2016 | B2 |
9301836 | Buchbinder et al. | Apr 2016 | B2 |
D755384 | Pesce et al. | May 2016 | S |
9326852 | Spenser | May 2016 | B2 |
9345573 | Nyuli et al. | May 2016 | B2 |
9421098 | Gifford, III et al. | Aug 2016 | B2 |
9439757 | Wallace et al. | Sep 2016 | B2 |
9480559 | Vidlund et al. | Nov 2016 | B2 |
9492273 | Wallace et al. | Nov 2016 | B2 |
9498332 | Hacohen et al. | Nov 2016 | B2 |
9532870 | Cooper et al. | Jan 2017 | B2 |
9554897 | Lane et al. | Jan 2017 | B2 |
9554899 | Granada et al. | Jan 2017 | B2 |
9561103 | Granada et al. | Feb 2017 | B2 |
9629716 | Seguin | Apr 2017 | B2 |
10045845 | Hacohen et al. | Aug 2018 | B2 |
10143552 | Wallace et al. | Dec 2018 | B2 |
10149761 | Granada et al. | Dec 2018 | B2 |
10154906 | Granada et al. | Dec 2018 | B2 |
10182908 | Tubishevitz et al. | Jan 2019 | B2 |
20010056295 | Solem | Dec 2001 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020099436 | Thornton et al. | Jul 2002 | A1 |
20040122503 | Campbell et al. | Jun 2004 | A1 |
20040143315 | Bruun et al. | Jul 2004 | A1 |
20040249433 | Freitag | Dec 2004 | A1 |
20040260394 | Douk et al. | Dec 2004 | A1 |
20050038494 | Eidenschink | Feb 2005 | A1 |
20050080430 | Wright, Jr. et al. | Apr 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050154443 | Linder et al. | Jul 2005 | A1 |
20050182483 | Osborne et al. | Aug 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20060004469 | Sokel | Jan 2006 | A1 |
20060015171 | Armstrong | Jan 2006 | A1 |
20060020333 | Lashinski et al. | Jan 2006 | A1 |
20060089627 | Burnett et al. | Apr 2006 | A1 |
20060161250 | Shaw | Jul 2006 | A1 |
20060178700 | Quinn | Aug 2006 | A1 |
20060212111 | Case et al. | Sep 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060271166 | Thill et al. | Nov 2006 | A1 |
20070055340 | Pryor | Mar 2007 | A1 |
20070056346 | Spenser et al. | Mar 2007 | A1 |
20070198077 | Cully et al. | Aug 2007 | A1 |
20070213810 | Newhauser et al. | Sep 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20080082083 | Forde et al. | Apr 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080140003 | Bei et al. | Jun 2008 | A1 |
20080147182 | Righini et al. | Jun 2008 | A1 |
20080167705 | Agnew | Jul 2008 | A1 |
20080234814 | Salahieh et al. | Sep 2008 | A1 |
20080255580 | Hoffman et al. | Oct 2008 | A1 |
20080294234 | Hartley et al. | Nov 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090112159 | Slattery et al. | Apr 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090248143 | Laham | Oct 2009 | A1 |
20090299449 | Styrc | Dec 2009 | A1 |
20090306768 | Quadri | Dec 2009 | A1 |
20100023120 | Holecek et al. | Jan 2010 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100076548 | Konno | Mar 2010 | A1 |
20100100167 | Bortlein et al. | Apr 2010 | A1 |
20100161036 | Pintor et al. | Jun 2010 | A1 |
20100234940 | Dolan | Sep 2010 | A1 |
20100331971 | Keranen et al. | Dec 2010 | A1 |
20110004296 | Lutter et al. | Jan 2011 | A1 |
20110071626 | Wright et al. | Mar 2011 | A1 |
20110077730 | Fenster | Mar 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110251678 | Eidenschink et al. | Oct 2011 | A1 |
20110282439 | Thill et al. | Nov 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120065464 | Ellis et al. | Mar 2012 | A1 |
20120089223 | Nguyen et al. | Apr 2012 | A1 |
20120123511 | Brown | May 2012 | A1 |
20120130473 | Norris et al. | May 2012 | A1 |
20120130474 | Buckley | May 2012 | A1 |
20120130475 | Shaw | May 2012 | A1 |
20120165915 | Melsheimer et al. | Jun 2012 | A1 |
20120179244 | Schankereli et al. | Jul 2012 | A1 |
20120296360 | Norris et al. | Nov 2012 | A1 |
20120310328 | Olson et al. | Dec 2012 | A1 |
20120330408 | Hillukka et al. | Dec 2012 | A1 |
20130006347 | McHugo | Jan 2013 | A1 |
20130018450 | Hunt | Jan 2013 | A1 |
20130018458 | Yohanan et al. | Jan 2013 | A1 |
20130041204 | Heilman et al. | Feb 2013 | A1 |
20130041451 | Patterson et al. | Feb 2013 | A1 |
20130046373 | Cartledge et al. | Feb 2013 | A1 |
20130123896 | Bloss et al. | May 2013 | A1 |
20130123900 | Eblacas et al. | May 2013 | A1 |
20130150945 | Crawford et al. | Jun 2013 | A1 |
20130150956 | Yohanan et al. | Jun 2013 | A1 |
20130158647 | Norris et al. | Jun 2013 | A1 |
20130166017 | Cartledge et al. | Jun 2013 | A1 |
20130166022 | Conklin | Jun 2013 | A1 |
20130172978 | Vidlund et al. | Jul 2013 | A1 |
20130211501 | Buckley et al. | Aug 2013 | A1 |
20130245742 | Norris | Sep 2013 | A1 |
20130261737 | Costello | Oct 2013 | A1 |
20130261738 | Clague et al. | Oct 2013 | A1 |
20130297013 | Klima et al. | Nov 2013 | A1 |
20130310928 | Morriss et al. | Nov 2013 | A1 |
20130331929 | Mitre et al. | Dec 2013 | A1 |
20140005778 | Buchhinder et al. | Jan 2014 | A1 |
20140018911 | Zhou et al. | Jan 2014 | A1 |
20140031928 | Murphy et al. | Jan 2014 | A1 |
20140046430 | Shaw | Feb 2014 | A1 |
20140081376 | Burkart et al. | Mar 2014 | A1 |
20140106951 | Brandon | Apr 2014 | A1 |
20140120287 | Jacoby et al. | May 2014 | A1 |
20140121763 | Duffy et al. | May 2014 | A1 |
20140135894 | Norris et al. | May 2014 | A1 |
20140135895 | Andress et al. | May 2014 | A1 |
20140142681 | Norris | May 2014 | A1 |
20140148891 | Johnson | May 2014 | A1 |
20140163690 | White | Jun 2014 | A1 |
20140172069 | Roeder et al. | Jun 2014 | A1 |
20140188210 | Beard et al. | Jul 2014 | A1 |
20140188221 | Chung et al. | Jul 2014 | A1 |
20140207231 | Hacohen et al. | Jul 2014 | A1 |
20140214159 | Vidlund et al. | Jul 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140257467 | Lane et al. | Sep 2014 | A1 |
20140257475 | Gross et al. | Sep 2014 | A1 |
20140277358 | Slazas | Sep 2014 | A1 |
20140277418 | Miller | Sep 2014 | A1 |
20140277422 | Ratz et al. | Sep 2014 | A1 |
20140277427 | Ratz et al. | Sep 2014 | A1 |
20140296962 | Cartledge et al. | Oct 2014 | A1 |
20140296969 | Tegels et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140343670 | Bakis et al. | Nov 2014 | A1 |
20140358224 | Tegels et al. | Dec 2014 | A1 |
20140379065 | Johnson et al. | Dec 2014 | A1 |
20140379076 | Vidlund et al. | Dec 2014 | A1 |
20150045881 | Lim | Feb 2015 | A1 |
20150094802 | Buchbinder et al. | Apr 2015 | A1 |
20150127097 | Neumann et al. | May 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150173897 | Raanini et al. | Jun 2015 | A1 |
20150272730 | Melnick et al. | Oct 2015 | A1 |
20150320556 | Levi et al. | Nov 2015 | A1 |
20150327994 | Morriss et al. | Nov 2015 | A1 |
20150328000 | Ratz et al. | Nov 2015 | A1 |
20150351904 | Cooper et al. | Dec 2015 | A1 |
20160106539 | Buchbinder et al. | Apr 2016 | A1 |
20160213473 | Hacohen et al. | Jul 2016 | A1 |
20160242902 | Morriss et al. | Aug 2016 | A1 |
20160310268 | Oba et al. | Oct 2016 | A1 |
20160317301 | Quad | Nov 2016 | A1 |
20160324640 | Gifford, III et al. | Nov 2016 | A1 |
20160367360 | Cartledge et al. | Dec 2016 | A1 |
20160367368 | Vidlund et al. | Dec 2016 | A1 |
20160374801 | Jimenez et al. | Dec 2016 | A1 |
20170056166 | Ratz et al. | Mar 2017 | A1 |
20170065407 | Hacohen et al. | Mar 2017 | A1 |
Number | Date | Country |
---|---|---|
0170262 | Feb 1986 | EP |
1264582 | Dec 2002 | EP |
2006070372 | Jul 2006 | WO |
2006089236 | Aug 2006 | WO |
2007059252 | May 2007 | WO |
2008029296 | Mar 2008 | WO |
2008070797 | Jun 2008 | WO |
2008103722 | Aug 2008 | WO |
2009091509 | Jul 2009 | WO |
2010006627 | Jan 2010 | WO |
2012024428 | Feb 2012 | WO |
2012048035 | Apr 2012 | WO |
2012127309 | Sep 2012 | WO |
2013059747 | Apr 2013 | WO |
2013078497 | Jun 2013 | WO |
2014022124 | Feb 2014 | WO |
2014076696 | May 2014 | WO |
2014145338 | Sep 2014 | WO |
2014164364 | Oct 2014 | WO |
2016093877 | Jun 2016 | WO |
2016125160 | Aug 2016 | WO |
2018029680 | Feb 2018 | WO |
2018039631 | Mar 2018 | WO |
Entry |
---|
Saturn Project; A novel solution for transcatheter heart valve replacement specifically designed to address clinical therapeutic needs on mitral valve: Dec. 2016, 8 pages. |
Georg Lutter, et al; “Percutaneous Valve Replacement: Current State and Futrue Prospects”, The Annals of Thoracic Surgery, vol. 78, pp. 2199-2206; Dec. 2004. |
Dusan Pavcnik, et al; “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement”, Radiology Apr. 1992: 183(1):151-4. |
Righini presentation EuroPCR May 2015 (Saturn)—(downloaded from: https://www.pcronline.com/Cases-resourcesimagges/Resources/Course-videos-slides/2015/Cardiovascularinnovation-pipeline-Mitral-and-tricuspid-valve-interventions.). |
EESR dated Jun. 29, 2017; Appln. No. 11809374.9. |
International Preliminary Report on Patentability dated May 19, 2015; PCT/IL2013/050937. |
ISR and WO dated Mar. 17, 2014; PCT/IL13/50937. |
ISR and WO dated Oct. 27, 2015; PCT/IL2015/050792. |
ISR and WO dated May 30, 2016; PCT/IL2016/050125. |
Invitation to pay Addition Fees dated Sep. 29, 2017; PCT/IL2017/050873. |
UK office action dated Feb. 8, 2017; Appln. No. GB16133219.3. |
USPTO NFOA dated Jan. 18, 2017 in connection with U.S. Appl. No. 14/626,267. |
USPTO NFOA dated Jan. 21, 2016 in connection with U.S. Appl. No. 14/237,264. |
USPTO NFOA dated Feb. 7, 2017 in connection with U.S. Appl. No. 14/689,608. |
USPTO NFOA dated Jul. 1, 2016 in connection with U.S. Appl. No. 14/161,921. |
USPTO NFOA dated Nov. 16, 2017 in connection with U.S. Appl. No. 15/354,504. |
USPTO NFOA dated Nov. 27, 2015 in connection with U.S. Appl. No. 14/626,267. |
USPTO NFOA dated Dec. 10, 2015 in connection with U.S. Appl. No. 14/237,258. |
USPTO NOA dated Apr. 19, 2018 in connection with U.S. Appl. No. 15/354,504. |
USPTO NOA dated Jul. 1, 2016 in connection with U.S. Appl. No. 14/442,541. |
USPTO NOA dated Sep. 29, 2016 in connection with U.S. Appl. No. 14/442,541. |
USPTO NOA dated Oct. 16, 2013 in connection with U.S. Appl. No. 13/675,119. |
USPTO NOA dated Dec. 13, 2013 in connection with U.S. Appl. No. 13/675,119. |
USPTO RR dated Jan. 20, 2016 in connection with U.S. Appl. No. 14/161,921. |
An International Search Report and a Written Opinion both dated May 13, 2019, which issued during the prosecution of Applicant's PCT/IL2018/051350. |
An International Search Report and a Written Opinion both dated Apr. 5, 2019, which issued during the prosecution of Applicant's PCT/IL2019/050142. |
An International Search Report and a Written Opinion both dated Jan. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2018/051122. |
An International Search Report and a Written Opinion both dated Dec. 5, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050725. |
An International Preliminary Report on Patentability dated Feb. 12, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050873. |
An International Preliminary Report on Patentability dated Feb. 5, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050849. |
An Office Action dated Mar. 25, 2019, which issued during the prosecution of European Patent Application No. 14710060.6. |
An Office Action dated Oct. 25, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004. |
An Office Action dated Mar. 4, 2019, which issued during the prosecution of U.S. Appl. No. 14/763,004. |
An Office Action dated Jan. 9, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920. |
An Office Action dated Jan. 30, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501. |
An Office Action dated Feb. 5, 2019, which issued during the prosecution of U.S. Appl. No. 15/899,858. |
An Office Action dated May 23, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659. |
An Office Action dated May 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032. |
An International Search Report and a Written Opinion both dated Nov. 9, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050869. |
Number | Date | Country | |
---|---|---|---|
20180344455 A1 | Dec 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15354504 | Nov 2016 | US |
Child | 16100718 | US | |
Parent | 14442541 | US | |
Child | 15354504 | US | |
Parent | 13675119 | Nov 2012 | US |
Child | 14442541 | US |